ACHP Statement on CY 2025 Advance Notice for Medicare Advantage and Part D
ACHP issued a statement in response to CMS’ CY 2025 Advance Notice for Medicare Advantage and Part D.
ACHP issued a statement in response to CMS’ CY 2025 Advance Notice for Medicare Advantage and Part D.
ACHP submitted a response to an RFI from the National Institute of Standards and Technology on the exercise of march-in rights.
ACHP submitted a response to an RFI from Senator Bill Cassidy (R-LA) on access to cell and gene therapies.
ACHP strongly supports CMS’ proposed CY 2025 Medicare C & D rule, which supports consumer choice and caps broker compensation.
ACHP supports CMS’ proposals to reform broker agent compensation and urges immediate implementation to support and improve the Medicare Advantage and Part D programs.
ACHP is the voice of a unique approach in health care today, one that puts the patient at the center with plans and clinical teams collaborating to improve health outcomes and reduce costs. Our advocacy focuses on providing policymakers with tested solutions, rooted in a model that is proven to deliver better value for patients, employers and taxpayers.